The study showed that patients taking semaglutide were 24% less likely to experience major kidney problems compared to those taking a placebo, and they also had a lower risk of death
Leveraging the University of California Health Data Warehouse enabled a realworld analysis of 6,871 patients with primary colon cancer and rigorous adjustment strategies to probe whether GLP1 RA exposure relates to fiveyear mortality. At the end of the study, researchers found that participants with colon cancer taking GLP-1 medications had a 15.5% mortality risk within 5 years, compared to 37.1% in participants not taking the drugs
So say no more to your nausea or upset stomach
640 In the DPN study, tanezumab provided effective pain reduction in DPN, with no safety concerns observed
HSMGSH metabolism prevents GSH:GSSG imbalance In the cytosol, GSH and GSSG levels have been reported to be around 10 mmol L 1 and 200 nmol L 1 , respectively, determining a cytosolic GSH redox potential ( E GSH ) of 320 mV 16